CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
BI 425809 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03905096
NCT03905096Phase 1Completed

A Study to Investigate the Effects of Donepezil on the Pharmacokinetics of BI 425809 and Vice Versa in Healthy Male and Female Subjects (Open-label, Two-treatment, Two-period, One Fixed Sequence Cross-over Design)

Boehringer Ingelheim·interventional·Posted Apr 5, 2019·Updated Feb 17, 2021

In Brief

A Phase 1 clinical trial evaluating BI 425809 and Donepezil for Healthy. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The main objective of Part 1of this trial is to investigate the effect of co-administration of multiple doses of donepezil on the single-dose pharmacokinetics of BI 425809 in healthy subjects. In Part 2 the main objective is the investigation of the effect of co-administration of multiple doses of BI 425809 on the single-dose pharmacokinetics of donepezil in healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedApr 5, 2019
Enrollment StartApr 12, 2019
Primary CompletionAug 30, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.2 years ago

Interventions

BI 425809drug

Film coated tablet

Donepezildrug

Film coated tablet